BUCCISANO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 44.301
EU - Europa 4.179
AS - Asia 1.195
SA - Sud America 44
OC - Oceania 35
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 13
Totale 49.801
Nazione #
US - Stati Uniti d'America 44.248
DE - Germania 1.176
IT - Italia 775
CN - Cina 688
UA - Ucraina 613
IE - Irlanda 544
GB - Regno Unito 288
KR - Corea 231
FR - Francia 178
SE - Svezia 142
FI - Finlandia 137
RU - Federazione Russa 132
IN - India 49
PL - Polonia 47
CA - Canada 40
NL - Olanda 37
AU - Australia 31
BE - Belgio 28
IR - Iran 25
EG - Egitto 24
JP - Giappone 24
HK - Hong Kong 23
AT - Austria 19
VN - Vietnam 19
BR - Brasile 18
UZ - Uzbekistan 18
SG - Singapore 15
PH - Filippine 14
TR - Turchia 14
ES - Italia 13
MX - Messico 13
TH - Thailandia 12
PE - Perù 11
CH - Svizzera 10
CL - Cile 10
EU - Europa 9
TW - Taiwan 9
MY - Malesia 8
PK - Pakistan 8
SA - Arabia Saudita 8
ID - Indonesia 7
IQ - Iraq 7
PT - Portogallo 7
RO - Romania 7
A2 - ???statistics.table.value.countryCode.A2??? 4
GR - Grecia 4
IL - Israele 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
AR - Argentina 3
BD - Bangladesh 3
NZ - Nuova Zelanda 3
RS - Serbia 3
BH - Bahrain 2
CO - Colombia 2
EE - Estonia 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
MA - Marocco 2
NG - Nigeria 2
QA - Qatar 2
SD - Sudan 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DK - Danimarca 1
FJ - Figi 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
PS - Palestinian Territory 1
SN - Senegal 1
TN - Tunisia 1
Totale 49.801
Città #
Woodbridge 13.566
Wilmington 11.985
Houston 9.181
Fairfield 1.533
Ann Arbor 1.086
Chandler 1.086
Ashburn 859
Seattle 655
Jacksonville 535
Cambridge 531
Dublin 488
Dearborn 384
Medford 352
New York 346
Rome 281
Beijing 253
Lawrence 164
Zhengzhou 151
Boardman 101
San Diego 82
Milan 64
Menlo Park 60
Mülheim 59
Creede 54
Redwood City 46
Engelhard 43
London 41
Shanghai 40
Nanjing 39
Hefei 34
Center 33
Norwalk 29
Kraków 27
Bologna 25
Brussels 25
Kunming 25
Seoul 25
University Park 24
Falls Church 22
Hangzhou 21
Palo Alto 21
Toronto 19
Mountain View 16
Guangzhou 15
Los Angeles 15
Nürnberg 15
Pune 15
Santa Clara 15
Verona 15
Dong Ket 14
Helsinki 13
Nanchang 12
Bang Bai Mai 11
Chicago 11
Chiswick 11
Lima 11
Naples 11
Saint Petersburg 11
Hackensack 10
Paris 10
Florence 9
Fuzhou 9
Kilburn 9
Monte Vista 9
Nuremberg 9
San Jose 9
Detroit 8
Groningen 8
Hounslow 8
Wuhan 8
Birmingham 7
Hebei 7
Innsbruck 7
Lappeenranta 7
Mumbai 7
Phoenix 7
Redmond 7
Roebling 7
San Francisco 7
Torre Del Greco 7
Warsaw 7
Washington 7
Alexandria 6
Cairo 6
Jinan 6
Kuala Lumpur 6
Latina 6
Shenyang 6
Turin 6
Bari 5
Brisbane 5
Chengdu 5
Diyarbakır 5
Giza 5
Hanoi 5
Izmir 5
Jeddah 5
Madrid 5
Montreal 5
New Bedfont 5
Totale 44.893
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 599
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 539
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 474
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 466
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 456
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 447
An unusual endoscopic finding in a patient with melena: Multiple gastric ulcers of regular shape 444
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 440
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 439
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 437
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 436
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 434
CD7 expression in acute myeloid leukemia 430
Clinical significance of CD38 expression in chronic lymphocytic leukemia 425
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 420
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 420
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 419
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 419
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 417
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance 416
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 415
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 413
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 412
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 411
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 411
Biological features of acute myeloid leukemia in the elderly 411
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 410
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 410
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 407
Cord blood transplantation in adults with acute myeloid leukaemia. 407
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 406
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 405
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 401
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 398
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 398
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 396
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 393
AML-M0: a biological and clinical profile 392
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 391
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 387
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 386
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 380
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 380
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 377
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 375
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 374
Blood stem cell processing 372
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 372
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 371
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 371
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 371
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study 370
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 370
Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery 368
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 368
P-glycoprotein expression in de novo acute myeloid leukemia 367
Biological pattern of AML-M0 versus AML-M1: Response 367
Azacitidine for the treatment of patients with acute myeloid leukemia 364
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 364
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 363
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 363
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 362
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 362
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 358
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 358
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 354
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 354
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 354
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 353
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study 352
Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors 352
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 351
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 350
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 347
Monitoring of minimal residual disease in acute myeloid leukemia 347
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia 346
Outcomes of allogeneic stem cell transplantation for secondary therapy-related acute myeloid leukaemia 346
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 345
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 345
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. 344
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 343
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 342
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 341
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 340
Treatment of low-blast count AML using hypomethylating agents 340
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 339
Reversible hyporegenerative anemia during natalizumab treatment 338
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 337
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 334
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 333
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 333
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 331
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 330
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 329
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 327
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 320
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission? 319
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 318
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 316
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 315
Totale 38.149
Categoria #
all - tutte 99.005
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.005


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.273 0 0 0 0 0 0 0 0 0 0 0 1.273
2019/202012.840 1.053 1.080 898 1.156 1.152 1.411 1.247 1.109 1.055 1.076 733 870
2020/20217.478 840 865 745 1.008 769 713 951 711 229 219 328 100
2021/20221.970 66 193 81 67 54 194 131 129 167 177 136 575
2022/20232.972 285 232 219 296 210 575 350 202 334 51 161 57
2023/20241.539 138 48 202 49 139 511 78 112 42 48 46 126
Totale 50.441